Department of Urology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021 Nov;165(4):375-379. doi: 10.5507/bp.2021.003. Epub 2021 Feb 22.
Placental Growth Factor (PlGF) plays a crucial role in angiogenesis and was identified as a potential prognostic biomarker in various types of cancer. Therefore, we evaluated the diagnostic accuracy and prognostic value of PlGF serum concentration in patients with clear cell renal cell carcinoma (ccRCC).
A total of 49 patients subjected to partial or radical nephrectomy for ccRCC [localized without relapse (lccRCC; n=31), localized with later relapse (rccRCC; n=8), primary metastatic cancer (mccRCC; n=10); median of follow-up 4.4 years] were enrolled in a prospective study to assess the significance of PlGF serum concentration. PlGF was measured prior to surgery and 3 months postoperatively. Our control group consisted of 38 healthy subjects.
PlGF serum concentration was significantly higher in ccRCC compared to controls (P=0.002). The cut-off value of PlGF concentration for the risk of ccRCC was determined at 12.71 pg/mL (AUC=0.729; P=0.0001). Prior to surgery, among ccRCC subgroups, significantly higher PlGF concentration was detected in mccRCC compared to lccRCC (P=0.002). Postoperatively, we observed a tendency to higher PlGF serum concentration in rccRCC compared to lccRCC subgroup, however without significance (P=0.17). The cut-off value for the risk of relapse was 11.41 pg/mL (AUC=0.792; P=0.0003). In subjects with localized ccRCC with PlGF concentration below 11.41 pg/mL 3-years cancer specific survival was 93% compared to 61% in subject with concentration above the cut-off value (P=0.018).
Based on our findings, PlGF serum concentration seems to be a useful biomarker in diagnostics and prediction of prognosis in ccRCC.
胎盘生长因子（PlGF）在血管生成中起着至关重要的作用，并且已被鉴定为多种癌症的潜在预后生物标志物。因此，我们评估了 PlGF 血清浓度在透明细胞肾细胞癌（ccRCC）患者中的诊断准确性和预后价值。
共纳入 49 例行部分或根治性肾切除术的 ccRCC 患者[局限性无复发（lccRCC；n=31）、局限性后复发（rccRCC；n=8）、原发性转移性癌症（mccRCC；n=10）；中位随访时间为 4.4 年]进行前瞻性研究，以评估 PlGF 血清浓度的意义。PlGF 在术前和术后 3 个月进行测量。我们的对照组由 38 名健康受试者组成。
ccRCC 患者的 PlGF 血清浓度明显高于对照组（P=0.002）。PlGF 浓度的截断值确定为 12.71 pg/mL（AUC=0.729；P=0.0001），用于 ccRCC 的风险。术前，在 mccRCC 亚组中，PlGF 浓度明显高于 lccRCC（P=0.002）。术后，我们观察到 rccRCC 亚组的 PlGF 血清浓度有升高的趋势，但无统计学意义（P=0.17）。复发风险的截断值为 11.41 pg/mL（AUC=0.792；P=0.0003）。在 PlGF 浓度低于 11.41 pg/mL 的局限性 ccRCC 患者中，3 年癌症特异性生存率为 93%，而浓度高于截断值的患者为 61%（P=0.018）。
根据我们的研究结果，PlGF 血清浓度似乎是诊断和预测 ccRCC 预后的有用生物标志物。
